Bordeaux, France, Cambridge (MA), USA / October 20th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced that an international team composed of 3 PhD students from King’s College London has been awarded the Stem Cell SpaceShot grant. With this $100,000 research funding, Matthew Wai Heng CHUNG, Cher Shen KIAR & Sofia SYNTAKA will explore the reprogramming of stem cell-derived macrophages, with the aim of repairing neuronal damage, such as spinal cord injury. [Read more…]
Greenstone Bio Secures $1.3M from CIRM for iPSC-derived Cardiovascular Cell Technologies
CIRM awards $1.3M to Greenstone Bio for stem cell research involving iPSC-derived cardiovascular cells accelerated by artificial intelligence and machine learning.
Palo Alto, CA, Oct 04, 2022 – Greenstone Biosciences, Inc. (“Greenstone Bio”), a commercial-stage computational biology company, announces that the Company has received a DISC0 grant funding from the California Institute of Regenerative Medicine (CIRM). [Read more…]
TreeFrog Therapeutics moves to GMP manufacturing with cell encapsulation device delivered by Invetech
Bordeaux, France / October 11th, 2022 – TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. [Read more…]
8th Perinatal Stem Cell Society Congress/Workshop Coming Soon
The 8th Perinatal Stem Cell Society Congress/Workshop is taking place November 3, 2022, at the Westin Beach Resort in Fort Lauderdale, FL.
$599 Early Bird Ticket Sales Close Oct. 15th
After Oct. 15th the price is $899
Please register here
As a patient advocate, my aim is to create affordable access to safe stem cell and biologic therapies in the United States. There is an opportunity to work with FDA at this time to make substantial and long-lasting changes to the IND pathways. I have called this one-day workshop so that the industry can come together, not to challenge the FDA, but to work with FDA to find solutions that will enable access to life changing therapies for patients in the U.S. [Read more…]
Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement
Fully integrated companies streamline access to genetically modified stem cells for clinical development
October 6, 2022, Seattle, Washington – Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients. [Read more…]
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 201
- Next Page »